BHVN Stock Recent News
BHVN LATEST HEADLINES
NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE: BHVN) of a class action securities lawsuit.
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, inclusive (the “Class Period”). Biohaven investors have until September 12, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR BIOHA.
LOS ANGELES , July 21, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).
NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).
Cash, cash equivalents, marketable securities and restricted cash as of April 30, 2025 totaled approximately $518 million. Announced up to $600 million non-dilutive capital agreement with Oberland Capital Management LLC ("Oberland Capital"), with $250 million in gross proceeds received on closing on April 30, 2025, expected to support commercial launch planning in spinocerebellar ataxia ("SCA"), clinical development activities, and ongoing business operations.
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE:BHVN).
NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or the "Company") (NYSE: BHVN).